Wedbush Cuts Price Target on Maze Therapeutics to $48 From $58, Keeps Outperform Rating

Maze Therapeutics prices $150 million equity offering

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, AT&T, Yesway

BUZZ-Maze Therapeutics jumps on $150 mln share offering for kidney disease drugs

Maze Therapeutics publishes corporate presentation on genetics-driven kidney and metabolic disease pipeline

BRIEF-Maze Therapeutics Announces $150 Million Registered Offering

Maze Therapeutics prices $150 million follow-on stock offering at $23.5 per share

Maze Therapeutics Inc - Prices 5,540,000 Shares at $23.50 per Share

Maze Therapeutics Is Maintained at Buy by Truist Securities

Maze Therapeutics price target lowered to $64 from $68 at Truist

Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Immuneering (IMRX) and Maze Therapeutics, Inc. (MAZE)

Wall Street Analysts Are Bullish on Top Healthcare Picks

Maze Therapeutics President R&D, CMO Harold Bernstein disposes shares worth $0.4 million

Maze SVP Finance Amy Bachrodt disposes Maze Therapeutics shares worth $0.1 million

Calendar of U.S. Earnings Expected in the Week Ahead

Maze Therapeutics CSBO Atul Dandekar disposes of common shares worth $0.2 million

Maze Therapeutics director Neil Kumar files initial beneficial ownership statement

Maze Therapeutics Is Maintained at Overweight by JP Morgan

Stock Track | Maze Therapeutics Soars 5.65% Intraday on Positive Analyst Ratings and Target Price Increases